Literature DB >> 22496040

Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.

Robert Bradley Troxler1, Wynton C Hoover, LaCrecia J Britton, Andrea M Gerwin, Steven M Rowe.   

Abstract

BACKGROUND: Accelerated lung function decline in cystic fibrosis (CF) is associated with mucoid Pseudomonas aeruginosa infection. Recent data suggest that mucoid P. aeruginosa may amenable to elimination from the airway. We aim to determine whether the initiation of an aggressive antibiotic eradication regimen upon initial discovery of mucoid P. aeruginosa in the CF airway could be successful in clearing the organism from the CF lung.
METHODS: We performed a retrospective analysis of patients with CF who demonstrated new growth of mucoid P. aeruginosa in an airway culture between January 2003 and December 2008. The primary endpoint was clearance of mucoid P. aeruginosa, based upon the Leeds criteria, with no further growth of mucoid P. aeruginosa cultures within 12 months of the initial discovery and treatment. Factors associated with successful clearance were also evaluated.
RESULTS: Forty-eight of 355 patients with CF had a new diagnosis of mucoid P. aeruginosa during the study period; 15 patients underwent an eradication attempt, while 33 patients received no increase in therapy. We observed clearance of mucoid P. aeruginosa in 73.3% of patients undergoing an eradication attempt, whereas 36.6% of those that did not undergo attempted eradication cleared the organism at 1 year (P < 0.05). Prolonged mucoid P. aeruginosa airway clearance (>24 months) for mucoid P. aeruginosa was seen in 60.0% in subjects undergoing eradication compared to 21.2% (P = 0.02) in control patients. At the study conclusion, lung function was greater in subjects who underwent an eradication attempt than in patients who did not undergo an eradication attempt (FEV(1) %: 91.7% vs. 75.0%, P = 0.04).
CONCLUSIONS: Clearance of initial mucoid P. aeruginosa from the airways of select patients with CF is possible with current antibiotic regimens, and the attempt may be associated with improved lung function.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496040      PMCID: PMC3707148          DOI: 10.1002/ppul.22543

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  30 in total

1.  Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.

Authors:  R L Henry; C M Mellis; L Petrovic
Journal:  Pediatr Pulmonol       Date:  1992-03

2.  Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate.

Authors:  N A Hodges; C A Gordon
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Authors:  Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Margaret Rosenfeld; Ann Yunker; Nicole Hamblett; Frank Accurso; Mark Dovey; Peter Hiatt; Michael W Konstan; Richard Moss; George Retsch-Bogart; Jeffrey Wagener; David Waltz; Robert Wilmott; Pamela L Zeitlin; Bonnie Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

4.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1997-05

5.  Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis.

Authors:  J P Gutierrez; K Grimwood; D S Armstrong; J B Carlin; R Carzino; A Olinsky; C F Robertson; P D Phelan
Journal:  Eur Respir J       Date:  2001-02       Impact factor: 16.671

6.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

7.  Early infection and progression of cystic fibrosis lung disease.

Authors:  Christian Koch
Journal:  Pediatr Pulmonol       Date:  2002-09

8.  Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Tim W R Lee; Keith G Brownlee; Steven P Conway; Miles Denton; James M Littlewood
Journal:  J Cyst Fibros       Date:  2003-03       Impact factor: 5.482

9.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

Review 10.  Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.

Authors:  Margaret Rosenfeld; Bonnie W Ramsey; Ronald L Gibson
Journal:  Curr Opin Pulm Med       Date:  2003-11       Impact factor: 3.155

View more
  5 in total

1.  Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  J Cyst Fibros       Date:  2019-04-26       Impact factor: 5.482

Review 2.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

3.  Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Authors:  Sonya L Heltshe; Nicole Mayer-Hamblett; Jane L Burns; Umer Khan; Arthur Baines; Bonnie W Ramsey; Steven M Rowe
Journal:  Clin Infect Dis       Date:  2014-11-25       Impact factor: 9.079

Review 4.  [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

Authors:  A-M Dittrich
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

Review 5.  Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.

Authors:  Ana Margarida Sousa; Maria Olívia Pereira
Journal:  Pathogens       Date:  2014-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.